CN115515943B - 噁二唑衍生物 - Google Patents
噁二唑衍生物 Download PDFInfo
- Publication number
- CN115515943B CN115515943B CN202180036916.0A CN202180036916A CN115515943B CN 115515943 B CN115515943 B CN 115515943B CN 202180036916 A CN202180036916 A CN 202180036916A CN 115515943 B CN115515943 B CN 115515943B
- Authority
- CN
- China
- Prior art keywords
- compound
- disorders
- oxadiazol
- compounds
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020046138 | 2020-03-17 | ||
| JP2020-046138 | 2020-03-17 | ||
| PCT/JP2021/010628 WO2021187486A1 (ja) | 2020-03-17 | 2021-03-16 | オキサジアゾール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115515943A CN115515943A (zh) | 2022-12-23 |
| CN115515943B true CN115515943B (zh) | 2024-07-09 |
Family
ID=77768228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180036916.0A Active CN115515943B (zh) | 2020-03-17 | 2021-03-16 | 噁二唑衍生物 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20230265061A1 (https=) |
| EP (1) | EP4122923B1 (https=) |
| JP (2) | JP7637121B2 (https=) |
| KR (1) | KR20220154208A (https=) |
| CN (1) | CN115515943B (https=) |
| AU (1) | AU2021239631A1 (https=) |
| BR (1) | BR112022017530A2 (https=) |
| CA (1) | CA3170273A1 (https=) |
| DK (1) | DK4122923T3 (https=) |
| ES (1) | ES3041051T3 (https=) |
| FI (1) | FI4122923T3 (https=) |
| MX (1) | MX2022011483A (https=) |
| PH (1) | PH12022552373A1 (https=) |
| PT (1) | PT4122923T (https=) |
| TW (1) | TWI879917B (https=) |
| WO (1) | WO2021187486A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4122923T3 (da) * | 2020-03-17 | 2025-12-15 | Sumitomo Pharma Co Ltd | Oxadiazolderivat |
| JP7653399B2 (ja) | 2021-09-22 | 2025-03-28 | 住友ファーマ株式会社 | オキサジアゾール誘導体を含有する医薬組成物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1227978A (https=) * | 1968-09-13 | 1971-04-15 | ||
| TW200715993A (en) | 2005-06-15 | 2007-05-01 | Senomyx Inc | Bis-aromatic amides and their uses as sweet flavor modifiers, tastants, and taste enhancers |
| JP5015172B2 (ja) * | 2005-12-23 | 2012-08-29 | エフ．ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾロ−４−イル−オキサジアゾール誘導体 |
| SG177221A1 (en) * | 2006-12-15 | 2012-01-30 | Abbott Lab | Novel oxadiazole compounds |
| GB0723814D0 (en) * | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| RU2010142655A (ru) * | 2008-03-19 | 2012-04-27 | Ауриммед Фарма, Инк. (Us) | Соединение, пригодное для лечения болезней и нарушений центральной нервной системы, и способ его получения |
| US8691824B2 (en) * | 2008-08-04 | 2014-04-08 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| RU2011123777A (ru) * | 2008-11-14 | 2012-12-20 | ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. | Бифенилацетамидные производные |
| JP2012001537A (ja) * | 2010-05-19 | 2012-01-05 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体からなる医薬 |
| WO2011145669A1 (ja) * | 2010-05-19 | 2011-11-24 | 大日本住友製薬株式会社 | アミド誘導体 |
| US9199981B2 (en) | 2011-09-01 | 2015-12-01 | Novartis Ag | Compounds and compositions as C-kit kinase inhibitors |
| PL2772482T3 (pl) | 2011-10-27 | 2016-08-31 | Taisho Pharmaceutical Co Ltd | Pochodna azolu |
| JP2013221025A (ja) * | 2012-04-19 | 2013-10-28 | Dainippon Sumitomo Pharma Co Ltd | ビフェニルアセトアミド誘導体の製造方法及びその中間体 |
| US20150299178A1 (en) * | 2012-11-12 | 2015-10-22 | Lupin Limited | Thiazole Derivatives as Alpha 7 NACHR Modulators |
| JP6387669B2 (ja) * | 2013-04-26 | 2018-09-12 | 大正製薬株式会社 | アゾール誘導体を含有する医薬 |
| WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| TW201642855A (zh) * | 2015-03-10 | 2016-12-16 | 健臻公司 | 用於治療蛋白質病變之方法 |
| WO2017066103A1 (en) * | 2015-10-16 | 2017-04-20 | Aurimmed Pharma, Inc. | Novel compounds advantageous in the treatment of central nervous system diseases and disorders |
| CN108348527A (zh) * | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| DK4122923T3 (da) * | 2020-03-17 | 2025-12-15 | Sumitomo Pharma Co Ltd | Oxadiazolderivat |
-
2021
- 2021-03-16 DK DK21770862.7T patent/DK4122923T3/da active
- 2021-03-16 TW TW110109295A patent/TWI879917B/zh active
- 2021-03-16 FI FIEP21770862.7T patent/FI4122923T3/fi active
- 2021-03-16 CN CN202180036916.0A patent/CN115515943B/zh active Active
- 2021-03-16 MX MX2022011483A patent/MX2022011483A/es unknown
- 2021-03-16 EP EP21770862.7A patent/EP4122923B1/en active Active
- 2021-03-16 WO PCT/JP2021/010628 patent/WO2021187486A1/ja not_active Ceased
- 2021-03-16 KR KR1020227035750A patent/KR20220154208A/ko active Pending
- 2021-03-16 JP JP2022508381A patent/JP7637121B2/ja active Active
- 2021-03-16 ES ES21770862T patent/ES3041051T3/es active Active
- 2021-03-16 AU AU2021239631A patent/AU2021239631A1/en active Pending
- 2021-03-16 BR BR112022017530A patent/BR112022017530A2/pt unknown
- 2021-03-16 CA CA3170273A patent/CA3170273A1/en active Pending
- 2021-03-16 PT PT217708627T patent/PT4122923T/pt unknown
- 2021-03-16 US US17/905,847 patent/US20230265061A1/en active Pending
- 2021-03-16 PH PH1/2022/552373A patent/PH12022552373A1/en unknown
-
2022
- 2022-09-16 US US17/932,871 patent/US11718592B2/en active Active
-
2025
- 2025-02-14 JP JP2025022409A patent/JP2025081449A/ja active Pending
Non-Patent Citations (8)
| Title |
|---|
| CAS登记号 2372839-85-3.CAS REGISTRY 库.2019, * |
| CAS登记号 2372841-01-3.CAS REGISTRY 库.2019, * |
| CAS登记号 2391021-52-4.CAS REGISTRY库.2019, * |
| CAS登记号 2393258-12-1.CAS REGISTRY库.2019, * |
| CAS登记号 2395139-54-3.CAS REGISTRY 库.2019, * |
| CAS登记号 2395140-09-5.CAS REGISTRY 库.2019, * |
| CAS登记号 2398023-07-7.CAS REGISTRY 库.2020, * |
| CAS登记号 2399808-57-0.CAS REGISTRY库.2020, * |
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022552373A1 (en) | 2023-12-18 |
| US11718592B2 (en) | 2023-08-08 |
| ES3041051T3 (en) | 2025-11-06 |
| EP4122923A4 (en) | 2024-04-24 |
| JP7637121B2 (ja) | 2025-02-27 |
| TWI879917B (zh) | 2025-04-11 |
| KR20220154208A (ko) | 2022-11-21 |
| EP4122923B1 (en) | 2025-09-10 |
| BR112022017530A2 (pt) | 2022-10-18 |
| US20230092498A1 (en) | 2023-03-23 |
| CN115515943A (zh) | 2022-12-23 |
| FI4122923T3 (fi) | 2025-11-12 |
| US20230265061A1 (en) | 2023-08-24 |
| TW202146392A (zh) | 2021-12-16 |
| EP4122923A1 (en) | 2023-01-25 |
| AU2021239631A1 (en) | 2022-11-10 |
| WO2021187486A1 (ja) | 2021-09-23 |
| MX2022011483A (es) | 2022-10-07 |
| JPWO2021187486A1 (https=) | 2021-09-23 |
| CA3170273A1 (en) | 2021-09-23 |
| DK4122923T3 (da) | 2025-12-15 |
| PT4122923T (pt) | 2025-12-03 |
| AU2021239631A8 (en) | 2022-12-01 |
| JP2025081449A (ja) | 2025-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114901661B (zh) | 新型K-Ras G12C抑制剂 | |
| JP7470058B2 (ja) | 複素環化合物 | |
| WO2012117421A1 (en) | Histone deacetylase inhibitors | |
| JP2025081449A (ja) | オキサジアゾール誘導体 | |
| JPWO2011136269A1 (ja) | テトラヒドロベンゾチオフェン化合物 | |
| KR20150008891A (ko) | 알파 7 니코틴성 아세틸콜린 수용기 알로스테릭 조절제, 그의 유도체 및 그의 용도 | |
| CN117440955A (zh) | 具有食欲素-2受体激动剂活性的取代的酰胺大环化合物 | |
| KR20090114439A (ko) | 아실구아니딘 유도체 | |
| TW202003472A (zh) | 鈣蛋白酶(calpain)調節劑及其醫療用途 | |
| MX2014012992A (es) | Derivado de quinazolindiona. | |
| JPWO2017155050A1 (ja) | 芳香環化合物 | |
| EA031614B1 (ru) | Трициклические атропоизомерные соединения | |
| JPWO2016171248A1 (ja) | 複素環化合物 | |
| EA029313B1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| CN112752760B (zh) | 杂环化合物 | |
| CN120051467A (zh) | 2(1h)-吡啶亚胺衍生物 | |
| CN113754580A (zh) | 一种吡啶吗啉类化合物、其制备方法及其应用 | |
| TWI423967B (zh) | 醯胺衍生物及含有其之醫藥組合物 | |
| JP7653399B2 (ja) | オキサジアゾール誘導体を含有する医薬組成物 | |
| KR102428549B1 (ko) | 삼환식 화합물 및 암의 치료에서의 이의 용도 | |
| HK40086571A (en) | Oxadiazole derivative | |
| TWI254046B (en) | Novel 1-[1-(hetero)aryl-1-perhydroxyalkylmethyl]-piperazine compounds, process for their preparation and medicaments containing these compounds | |
| HK40086571B (en) | Oxadiazole derivative | |
| CN101262864A (zh) | 饱和o-杂环取代的烷酰胺 | |
| EA048061B1 (ru) | Производное оксадиазола |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |